Disclosed herein are p38α mitogen-activated protein kinase inhibitors, pharmaceutical compositions thereof, and therapeutic methods of using the p38α mitogen-activated protein kinase inhibitors.

Rare earth extractant compounds having the following structure:

##STR00001##

wherein R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are independently selected from alkyl groups containing 1-30 carbon atoms and optionally containing an ether or thioether linkage connecting between carbon atoms, provided that the total carbon atoms in R.sup.1, R.sup.2, R.sup.3, and R.sup.4 is at least 12; R.sup.5 and R.sup.6 are independently selected from hydrogen atom and alkyl groups containing 1-3 carbon atoms; and provided that at least one of the conditions (i)-(iv) apply as follows: presence of a distal branched group in at least one of R.sup.1-R.sup.4 (condition i), asymmetry in R.sup.1-R.sup.4 (condition ii), presence of amine-containing ring (condition iii), or presence of lactam ring (condition iv). Also described are hydrophobic water-insoluble solutions containing at least one extractant compound of Formula (1), as well as method for extracting rare earth elements from aqueous solution by contacting the aqueous solution with the water-insoluble solution.

Rare earth extractant compounds having the following structure:

##STR00001##

wherein R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are independently selected from alkyl groups containing 1-30 carbon atoms and optionally containing an ether or thioether linkage connecting between carbon atoms, provided that the total carbon atoms in R.sup.1, R.sup.2, R.sup.3, and R.sup.4 is at least 12; R.sup.5 and R.sup.6 are independently selected from hydrogen atom and alkyl groups containing 1-3 carbon atoms; and provided that at least one of the conditions (i)-(iv) apply as follows: presence of a distal branched group in at least one of R.sup.1-R.sup.4 (condition i), asymmetry in R.sup.1-R.sup.4 (condition ii), presence of amine-containing ring (condition iii), or presence of lactam ring (condition iv). Also described are hydrophobic water-insoluble solutions containing at least one extractant compound of Formula (1), as well as method for extracting rare earth elements from aqueous solution by contacting the aqueous solution with the water-insoluble solution.

This invention provides an isolated compound having the structure: ##STR00001##
or a salt thereof, processes for making the same and to compositions comprising pridopidine with these compounds.

This invention provides an isolated compound having the structure: ##STR00001##
or a salt thereof, processes for making the same and to compositions comprising pridopidine with these compounds.

Lipid nanoparticle compositions for delivery of nucleic acids are described. The lipid nanoparticle may contain a conformationally constrained ionizable lipid as part of the composition. These compositions may allow for delivery of cargo without the need for a targeting ligand.

The present invention relates to novel dopamine D2 receptor ligands. The invention further relates to functionally-biased dopamine D2 receptor ligands and the use of these compounds for treating or preventing central nervous system and systemic disorders associated with dysregulation of dopaminergic activity.

The invention provides compounds having the general formula I:

##STR00001##

and pharmaceutically acceptable salts thereof, wherein the variables R.sup.A, R.sup.AA, subscript n, ring A, X.sup.2, L, subscript m, X.sup.1, ring B, R.sup.1, and R.sup.N have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

The invention provides compounds having the general formula I:

##STR00001##

and pharmaceutically acceptable salts thereof, wherein the variables R.sup.A, R.sup.AA, subscript n, ring A, X.sup.2, L, subscript m, X.sup.1, ring B, R.sup.1, and R.sup.N have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

Disclosed herein are compounds having a structure of formula (I), compositions and methods useful for the treatment of a disease or infection, such as a viral infection (e.g., Ebola), cancer and obesity:

##STR00001##

wherein A is N or CR.sup.8; Z is

##STR00002## E is selected from optionally substituted alkyl, cycloalkyl, arylalkyl, cycloalkylalkyl, amino, alkoxy, cycloalkyloxy, and cycloalkylamino; R.sup.1 is selected from optionally substituted aryl and heteroaryl, R.sup.2 and R.sup.3 are independently selected from H, deutero, optionally substituted alkyl, haloalkyl, or R.sup.2 and R.sup.3, together with the carbon to which they are bound, combine to form a carbonyl; and R.sup.8 is selected from H, deutero, halo, hydroxyl, cyano, amino, alkyl, alkoxy, carboxy, alkoxycarbonyl, and aminocarbonyl, provided that E is not

##STR00003##